Boehringher Ingelheim makes progress in diabetes
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim is expanding rapidly into type 2 diabetes treatments, with plans to file its most advanced candidate, Ondero (BI1536) in 2010. The privately held German company has taken three antidiabetic compounds into the clinic, it announced at its second international R&D press conference last week.